Niyi Fadeyi, PhD
InduPro Therapeutics
Niyi Fadeyi, Ph.D., is Co-Founder and Vice President of Chemical Sciences at InduPro Therapeutics, where he leads the company’s discovery chemistry and chemical biology efforts, advancing innovative technologies for therapeutic target discovery and the development of differentiated medicines. His work spans the interface of chemistry, biology, and drug discovery, with a focus on translating fundamental scientific discoveries into novel therapeutic opportunities.
Prior to co-founding InduPro, Dr. Fadeyi was a founding member of Merck’s Exploratory Science Center, where he served as Head of Molecular Discovery and co-led the Cellular Chemistry team. He directed multidisciplinary efforts to discover novel therapeutic targets, establish innovative drug discovery platforms, and advance early-stage research across multiple therapeutic areas. He is a co-inventor of a pioneering light-powered protein microenvironment mapping technology that enables high-resolution characterization of protein neighborhoods.
Previously, Dr. Fadeyi was a Principal Scientist at Pfizer, where he led medicinal chemistry and chemical biology efforts across diverse therapeutic programs, including programs that progressed into clinical development.
Dr. Fadeyi completed his postdoctoral research as a UNCF/Merck Fellow at Harvard University with Professor Matthew Shair and earned his Ph.D. from Vanderbilt University under Professor Craig Lindsley. He also holds undergrtaduate degrees from Obafemi Awolowo University, Nigeria and a MSc from Tennessee State University.
He serves on the advisory board of the Journal of Medicinal Chemistry and has served on the Early Career Board of ACS Medicinal Chemistry Letters. He is also a co-founder of S.H.I.N.E., a nonprofit initiative dedicated to mentoring and advancing underrepresented students in STEM.
Prior to co-founding InduPro, Dr. Fadeyi was a founding member of Merck’s Exploratory Science Center, where he served as Head of Molecular Discovery and co-led the Cellular Chemistry team. He directed multidisciplinary efforts to discover novel therapeutic targets, establish innovative drug discovery platforms, and advance early-stage research across multiple therapeutic areas. He is a co-inventor of a pioneering light-powered protein microenvironment mapping technology that enables high-resolution characterization of protein neighborhoods.
Previously, Dr. Fadeyi was a Principal Scientist at Pfizer, where he led medicinal chemistry and chemical biology efforts across diverse therapeutic programs, including programs that progressed into clinical development.
Dr. Fadeyi completed his postdoctoral research as a UNCF/Merck Fellow at Harvard University with Professor Matthew Shair and earned his Ph.D. from Vanderbilt University under Professor Craig Lindsley. He also holds undergrtaduate degrees from Obafemi Awolowo University, Nigeria and a MSc from Tennessee State University.
He serves on the advisory board of the Journal of Medicinal Chemistry and has served on the Early Career Board of ACS Medicinal Chemistry Letters. He is also a co-founder of S.H.I.N.E., a nonprofit initiative dedicated to mentoring and advancing underrepresented students in STEM.
